

## INDEX OF TABLES

Table 1.3.1:	Pre-vaccination screening checklist	16
Table 1.3.2:	Responses to relevant conditions or circumstances identified by the pre-vaccination screening checklist	17
Table 1.3.3:	Live attenuated parenteral and oral vaccines	20
Table 1.3.4:	False contraindications to vaccination	21
Table 1.3.5:	Number of vaccine doses that should have been administered by the current age of the child (table to be used in conjunction with Catch-up Worksheet)	28
Table 1.3.6:	Minimum dose intervals for NIP vaccines for children <8 years of age (table to be used in conjunction with Catch-up Worksheet)	29
Table 1.3.7:	Minimum age for the first dose of vaccine in exceptional circumstances	30
Table 1.3.8:	Recommendations for Hib catch-up vaccination for children <5 years of age when doses have been delayed or missed	33
Table 1.3.9:	Recommendations for pneumococcal catch-up vaccination for low-risk children (including Indigenous children living in ACT, NSW, VIC and TAS) <2 years of age, when doses have been delayed or missed	34
Table 1.3.10:	Recommendations for pneumococcal catch-up vaccination for Indigenous children <2 years of age in NT, QLD, SA and WA, when doses have been delayed or missed	35
Table 1.3.11:	Recommendations for pneumococcal catch-up vaccination for children ≤5 years of age with underlying medical conditions	36
Table 1.3.12:	Catch-up schedules for individuals ≥8 years of age	38
Table 1.4.1:	Route of administration for vaccines commonly used in Australia	42
Table 1.4.2:	Recommended needle size, length and angle for administering vaccines	45
Table 1.5.1:	Clinical features which may assist differentiation between a vasovagal episode and anaphylaxis	62
Table 1.5.2:	Doses of intramuscular 1:1000 (one in one thousand) adrenaline for anaphylaxis	64
Table 1.5.3:	Contact details for notification of AEFI	66
Table 2.2.1:	Dose and routes of administration of commonly used vaccines in adult travellers (≥15 years of age)	80
Table 2.2.2:	Recommended lower age limits of travel vaccines for children	82
Table 2.3.1:	Vaccinations in pregnancy	86
Table 2.3.2:	Recommendations for vaccinations for solid organ transplant (SOT) recipients	95

Table 2.3.3:	Post-transplantation vaccination schedules for allogeneic and autologous haematopoietic stem cell transplant recipients	98
Table 2.3.4:	Immunological categories based on age-specific CD4 counts and percentage of total lymphocytes	99
Table 2.3.5:	Recommended intervals between either immunoglobulins or blood products and MMR, MMRV or varicella vaccination	103
Table 2.3.6:	Recommended vaccinations for those at risk of occupationally acquired vaccine-preventable diseases	105
Table 3.1.1:	Summary of Australian bat lyssavirus and rabies post-exposure treatment for non-immune individuals	117
Table 3.5.1:	Recommended dosages and schedules for use of the inactivated hepatitis A vaccines	143
Table 3.5.2:	Recommended doses of normal human immunoglobulin (NHIG) to be given as a single intramuscular injection to close contacts of hepatitis A cases	146
Table 3.6.1:	Hepatitis B and hepatitis A/hepatitis B combination vaccination schedules	155
Table 3.6.2:	Accelerated hepatitis B vaccination schedules	156
Table 3.6.3:	Post-exposure prophylaxis for non-immune individuals exposed to an HBsAg positive person	162
Table 3.9.1:	Recommended doses of influenza vaccine	189
Table 3.11.1:	Management of significant measles exposure using vaccination or normal human immunoglobulin (NHIG)	212
Table 3.12.1:	Early clinical management of suspected meningococcal disease	220
Table 3.14.1:	Recommended antimicrobial therapy and chemoprophylaxis regimens for pertussis in infants, children and adults	236
Table 3.15.1:	Summary table – pneumococcal vaccination schedule for children $\leq 9$ years of age (see also Section 1.3.5, <i>Catch-up</i> )	245
Table 3.15.2:	Underlying medical conditions predisposing children $\leq 9$ years of age to IPD	246
Table 3.15.3:	Revaccination with 23vPPV for people $\geq 10$ years of age	248
Table 3.17.1:	Interpretation and action for serological and skin test results	261
Table 3.18.1:	Age limits for dosing of oral rotavirus vaccines	269
Table 3.21.1:	Guide to tetanus prophylaxis in wound management	294
Table 3.24.1:	Recommendations for varicella vaccination with monovalent VV (currently available), and once MMRV vaccines are available	313
Table 3.24.2:	Zoster immunoglobulin-VF (ZIG) dose based on weight	320
Table 3.25.1:	Yellow fever endemic countries	324

## INDEX OF FIGURES

Figure 1.3.1:	Catch-up Worksheet for children <8 years of age	27
Figure 1.4.1:	The cuddle position for vaccination of a child <12 months of age	47
Figure 1.4.2:	Positioning an infant on an examination table for vaccination	48
Figure 1.4.3:	Positioning an older child in the cuddle position	49
Figure 1.4.4:	Positioning a child in the straddle position	50
Figure 1.4.5:	Diagram of the muscles of the thigh showing the anatomical markers to identify the recommended (vastus lateralis) injection site	52
Figure 1.4.6:	Photograph of the thigh showing the recommended (vastus lateralis) injection site	52
Figure 1.4.7:	Diagram showing the anatomical markers to identify the ventrogluteal injection site	53
Figure 1.4.8:	Photograph with infant prone across carer's lap, showing markers to identify the ventrogluteal injection site	54
Figure 1.4.9:	Diagram showing the anatomical markers to identify the deltoid injection site	55
Figure 1.4.10:	A subcutaneous injection into the deltoid area of the upper arm using a 25 gauge, 16 mm needle, inserted at a 45° angle	55
Figure 1.4.11:	Recommended technique for giving multiple vaccine injections to an infant <12 months of age into the anterolateral thigh	56
Figure 3.4.1:	<i>Haemophilus influenzae</i> type b (Hib) notifications, presumed Hib hospitalisations and deaths of children aged 0 to 4 years from Hib, Australia 1993 to 2005	133
Figure 3.5.1:	Notifications of hepatitis A in Australia, 1991 to 2006	140
Figure 3.6.1:	The influence of age of infection with the hepatitis B virus on the likelihood of becoming a hepatitis B carrier	150
Figure 3.7.1:	The dynamic relationship between HPV infection and cervical health	167
Figure 3.9.1:	Influenza notification rates 2003–2005 and hospitalisation rates 2002/2003 to 2004/2005, Australia, by age group	186
Figure 3.10.1:	Map of the Torres Strait	196
Figure 3.14.1:	Pertussis notifications by year of onset, Australia 1993–2005	228
Figure 3.17.1:	Q fever notifications and hospitalisations, Australia, 1993 to 2005, by month of diagnosis or admission	258